This activity is part of the Frankly Speaking with Dr. Frank Domino podcast series.


0.25 CME/CE Credit

Preventing Overdose Deaths with Naloxone: Harm Reduction vs Encouraging Use - Frankly Speaking EP 296Guest: Mariyan L. Montaque, DNP, FNP-BC
Music Credit: Richard Onorato

The number of drug overdoses in the United States continues to rise in tandem with the growing opioid epidemic. In 2020, nearly 92,000 people died from drug overdoses in the United States, which was an approximate 31% increase in just one year. This episode will highlight perceived barriers to harm reduction and show primary care providers how they can play a key role in overdose prevention. 

Episode Resources and Links: 

  • Bonner, L. (2022). As the opioid epidemic takes a turn for the worse, do we need more potent forms of naloxone?. Pharmacy Today, 28(3), 26.
  • Messmer, S., & Jarrett, J. (2022). When Naloxone Isn’t Enough. New England Journal of Medicine.
  • Tse, W. C., Djordjevic, F., Borja, V., Picco, L., Lam, T., Olsen, A., ... & Nielsen, S. (2022). Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a ‘moral hazard’associated with naloxone supply. International Journal of Drug Policy, 100, 103513.


Already listened on another platform?

Claim Credits

CME/CE Information

0.25 AMA PRA Category 1 Credits

Release Date: 10/3/2022

Expiration Date: 10/3/2024

Learning Objectives

  • Appraise the challenges and barriers to the use of naloxone for harm reduction during an overdose
  • Outline the strategies to help improve overdose prevention rates

Looking for more mental health CME?

Enroll in Mental Health Bootcamp, an on-demand curriculum with over 30 courses, a library of downloadable resources, and Q&A with faculty.  

Learn More


Frank J. Domino, MD

Professor, Family Medicine and Community Health,
University of Massachusetts Medical School, Worcester, MA

Learn More

Mariyan L. Montaque, DNP, FNP-BC

Instructor, Department of Family Medicine & Community Health, University of Massachusetts, Worcester, MA; Term Lecturer, Family Health Practicum, MGH Institute of Health Professions, Boston, MA; Visiting Assistant Professor, Department of Business Fitchburg State University, Fitchburg, MA. 

Learn More


The following financial relationships have been disclosed by faculty.

Frank J. Domino, MD

Has disclosed no relevant financial relationships. 

Mariyan L. Montaque, DNP, FNP-BC

Has disclosed no relevant financial relationships. 


Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For APRNs and PAs, AANPCB and NCCPA accept AMA PRA Category 1 Creditâ„¢ as the number of hours of participation (AANPCB) or as Category 1 CME credits (NCCPA).

Supporters and Partners

Commercial Supporter

Not Applicable

Education Partner

Not Applicable

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email or call (877) 477-4633.

Preventing Overdose Deaths with Naloxone: Harm Reduction vs Encouraging Use - Frankly Speaking EP 296